Legend: 
= Applied Session,
= Theme Session,
= Presenter, Sheraton Seattle Hotel & Towers = “S”
Washington State Convention & Trade Center = “CC”, Grand Hyatt Seattle = “H”
|
|
|
|
|
|
296
|
Tue, 8/8/06, 12:30 PM - 1:50 PM
|
CC-4C-2
|
|
Biopharmaceutical Section Roundtables with Lunch (fee event) - Roundtable Lnch
|
Biopharmaceutical Section
|
|
Organizer(s): Amit Bhattacharyya, GlaxoSmithKIine
|
|
TL10:
|
Contemporary Issues in Data Monitoring Committees —  David Kerr, Axio Research
|
|
TL11:
|
Controlling Error Rate in Safety Assessments from a Regulatory Perspective — Qian Li, U.S. Food and Drug Administration
|
|
TL12:
|
The Use of Targeted Designs in Clinical Trials — Gerald Crans, Eli Lilly and Company; Matthew Rotelli, Eli Lilly and Company
|
|
TL13:
|
CANCELLED - Statistical Concerns and Methodology Regarding Cognitive and Psychomotor Endpoints in Early Development (Phase I Trials) — Cynthia Gargano, Merck & Co., Inc.
|
|
TL14:
|
Preferred Methods of Dealing with Missing Data in Clinical Trials — Rukmini Rajagopalan, Abbott Laboratories
|
|
TL15:
|
Decision Rules Based on Multiple Endpoints in Clinical Trials — Alex Dmitrienko, Eli Lilly and Company
|
|
TL16:
|
Patient-Reported Outcomes: Issues Related to the Collection and Analysis, Including Measurement Reliability and Sensitivity — Tammy J. Massie, U.S. Food and Drug Administration
|
|
TL17:
|
Statistician's Role in PK/PD Modeling and Clinical Trial Simulation — Haiyuan Zhu, Merck Research Laboratories
|
|
TL18:
|
Retrospective Testing for Baseline Variables Comparability and Subsequent Covariate Adjustments for Significant Imbalance: Good Clinical Practice or Bad Statistical Practice? — Abdul Sankoh, sanofi-aventis
|
|
TL19:
|
CANCELLED - Statistical Issues Regarding Experimental Medicine — James Bolognese, Merck Research Laboratories
|
|
TL20:
|
Bayesian Dose-Finding Strategies for Phase I Oncology Trials — Glen Laird, Novartis Pharmaceuticals Corporation
|
|
TL21:
|
On the Evaluation of Benefit and Risk: the Tools We Have and How They Help — Yili Pritchett, Abbott Laboratories
|
|
TL22:
|
Use of Adaptive Clinical Trial Designs in Clinical Development for Product Registration — Laura Meyerson, Biogen Idec
|
| |
